Study of monogenic mitochondrial cardiomyopathies may yield insights into mitochondrial roles in cardiac development and disease. Here, we combined patient-derived and genetically engineered induced pluripotent stem cells (iPSCs) with tissue engineering to elucidate the pathophysiology underlying the cardiomyopathy of Barth syndrome (BTHS), a mitochondrial disorder caused by mutation of the gene encoding tafazzin (TAZ). Using BTHS iPSC-derived cardiomyocytes (iPSC-CMs), we defined metabolic, structural and functional abnormalities associated with TAZ mutation. BTHS iPSC-CMs assembled sparse and irregular sarcomeres, and engineered BTHS 'heart-on-chip' tissues contracted weakly. Gene replacement and genome editing demonstrated that TAZ mutation is necessary and sufficient for these phenotypes. Sarcomere assembly and myocardial contraction abnormalities occurred in the context of normal whole-cell ATP levels. Excess levels of reactive oxygen species mechanistically linked TAZ mutation to impaired cardiomyocyte function. Our study provides new insights into the pathogenesis of Barth syndrome, suggests new treatment strategies and advances iPSC-based in vitro modeling of cardiomyopathy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


NCBI Reference Sequence


  1. 1.

    et al. A novel X-linked gene, G4.5. is responsible for Barth syndrome. Nat. Genet. 12, 385–389 (1996).

  2. 2.

    et al. The enigmatic role of tafazzin in cardiolipin metabolism. Biochim. Biophys. Acta 1788, 2003–2014 (2009).

  3. 3.

    & Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am. J. Physiol. Cell Physiol. 292, C33–C44 (2007).

  4. 4.

    , , & Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005).

  5. 5.

    , , & Ensembles of engineered cardiac tissues for physiological and pharmacological study: heart on a chip. Lab Chip 11, 4165–4173 (2011).

  6. 6.

    et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).

  7. 7.

    et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618–630 (2010).

  8. 8.

    , , & Feeder-free derivation of human induced pluripotent stem cells with messenger RNA. Sci. Rep. 2, 657 (2012).

  9. 9.

    et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 489, 322–325 (2012).

  10. 10.

    et al. Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS ONE 6, e23657 (2011).

  11. 11.

    et al. NKX2–5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nat. Methods 8, 1037–1040 (2011).

  12. 12.

    et al. Phospholipid abnormalities in children with Barth syndrome. J. Am. Coll. Cardiol. 42, 1994–1999 (2003).

  13. 13.

    et al. Bloodspot assay using HPLC-tandem mass spectrometry for detection of Barth syndrome. Clin. Chem. 54, 371–378 (2008).

  14. 14.

    , , & Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. Toxicol. Sci. 130, 117–131 (2012).

  15. 15.

    et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008).

  16. 16.

    et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 31, 898–907 (2013).

  17. 17.

    et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).

  18. 18.

    et al. The permeability transition pore controls cardiac mitochondrial maturation and myocyte differentiation. Dev. Cell 21, 469–478 (2011).

  19. 19.

    & Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J. Mol. Cell. Cardiol. 27, 849–856 (1995).

  20. 20.

    , , , & Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip 13, 3599–3608 (2013).

  21. 21.

    et al. Muscular thin films for building actuators and powering devices. Science 317, 1366–1370 (2007).

  22. 22.

    et al. Generation of functional ventricular heart muscle from mouse ventricular progenitor cells. Science 326, 426–429 (2009).

  23. 23.

    , , & Myofibrillar architecture in engineered cardiac myocytes. Circ. Res. 103, 340–342 (2008).

  24. 24.

    , , & Biohybrid thin films for measuring contractility in engineered cardiovascular muscle. Biomaterials 31, 3613–3621 (2010).

  25. 25.

    et al. Role of calcium-independent phospholipase A2 in the pathogenesis of Barth syndrome. Proc. Natl. Acad. Sci. USA 106, 2337–2341 (2009).

  26. 26.

    et al. Linoleic acid supplementation of Barth syndrome fibroblasts restores cardiolipin levels: implications for treatment. J. Lipid Res. 44, 560–566 (2003).

  27. 27.

    et al. Natural history of Barth syndrome: a national cohort study of 22 patients. Orphanet J. Rare Dis. 8, 70 (2013).

  28. 28.

    Oxidative stress and sarcomeric proteins. Circ. Res. 112, 393–405 (2013).

  29. 29.

    et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 4, 130ra47 (2012).

  30. 30.

    et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12, 101–113 (2013).

  31. 31.

    et al. Disease-specific induced pluripotent stem cells. Cell 134, 877–886 (2008).

  32. 32.

    et al. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat. Biotechnol. 27, 1033–1037 (2009).

  33. 33.

    et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 103, 1256–1263 (2001).

  34. 34.

    et al. Diagnosis and therapeutic evaluation of a pediatric case of cardiomyopathy using phosphorus-31 nuclear magnetic resonance spectroscopy. J. Am. Coll. Cardiol. 5, 745–749 (1985).

  35. 35.

    & PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science 340, 471–475 (2013).

  36. 36.

    , , & Co-occupancy by multiple cardiac transcription factors identifies transcriptional enhancers active in heart. Proc. Natl. Acad. Sci. USA 108, 5632–5637 (2011).

  37. 37.

    et al. Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome. Anal. Biochem. 15, 230–237 (2009).

  38. 38.

    , & Sarcomere alignment is regulated by myocyte shape. Cell Motil. Cytoskeleton 65, 641–651 (2008).

  39. 39.

    , , , & Geometric control of cell life and death. Science 276, 1425–1428 (1997).

  40. 40.

    et al. Three-dimensional multi-scale line filter for segmentation and visualization of curvilinear structures in medical images. Med. Image Anal. 2, 143–168 (1998).

  41. 41.

    On-line construction of the convex hull of a simple polyline. Inf. Process. Lett. 25, 11–12 (1987).

  42. 42.

    et al. T-tubule remodeling during transition from hypertrophy to heart failure. Circ. Res. 107, 520–531 (2010).

  43. 43.

    & in Engineering Societies Monographs 5 (McGraw-Hill, 1959).

  44. 44.

    The tension of metallic films deposited by electrolysis. Proc. R. Soc. Lond. 82, 172–175 (1909).

Download references


This work supported by the Barth Syndrome Foundation, the Boston Children's Hospital Translational Investigator Service, the US National Institutes of Health (NIH) NHLBI Progenitor Cell Biology Consortium (NIH U01 HL100401 and U01 HL100408), NIH RC1 HL099618, NIH UH2 TR000522 and charitable donations from E. Marram, K. Carpenter and G.F. Smith.

Author information

Author notes

    • Gang Wang
    •  & Megan L McCain

    These authors contributed equally to this work.


  1. Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts, USA.

    • Gang Wang
    • , Aibin He
    • , Dawei Jiang
    • , Donghui Zhang
    • , Lior Zangi
    • , Judith Geva
    • , Amy E Roberts
    • , Qing Ma
    • , Jian Ding
    • , Jinghai Chen
    • , Da-Zhi Wang
    • , Kai Li
    •  & William T Pu
  2. Wyss Institute for Biologically Inspired Engineering, School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.

    • Megan L McCain
    • , Luhan Yang
    • , Francesco Silvio Pasqualini
    • , Ashutosh Agarwal
    • , Hongyan Yuan
    • , George M Church
    •  & Kevin Kit Parker
  3. Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.

    • Luhan Yang
    •  & George M Church
  4. Department of Medicine, Division of Genetics, Boston Children's Hospital, Boston, Massachusetts, USA.

    • Amy E Roberts
  5. Allele Biotechnology & Pharmaceuticals, Inc., San Diego, California, USA.

    • Jiwu Wang
  6. Department of Photobiology and Bioengineering, The Scintillon Institute, San Diego, California, USA.

    • Jiwu Wang
  7. Department of Clinical Chemistry and Pediatrics, Laboratory of Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, The Netherlands.

    • Ronald J A Wanders
    • , Wim Kulik
    •  & Frédéric M Vaz
  8. Department of Pathology, Center for Cardiovascular Biology and Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA.

    • Michael A Laflamme
    •  & Charles E Murry
  9. Department of Bioengineering, Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA.

    • Charles E Murry
  10. Department of Medicine and Cardiology, Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA.

    • Charles E Murry
  11. Department of Cell and Molecular Biology and Medicine, Karolinska Institutet, Stockholm, Sweden.

    • Kenneth R Chien
  12. Division of Metabolism, Kennedy Krieger Institute, Baltimore, Maryland, USA.

    • Richard I Kelley
  13. Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA.

    • Kevin Kit Parker
    •  & William T Pu


  1. Search for Gang Wang in:

  2. Search for Megan L McCain in:

  3. Search for Luhan Yang in:

  4. Search for Aibin He in:

  5. Search for Francesco Silvio Pasqualini in:

  6. Search for Ashutosh Agarwal in:

  7. Search for Hongyan Yuan in:

  8. Search for Dawei Jiang in:

  9. Search for Donghui Zhang in:

  10. Search for Lior Zangi in:

  11. Search for Judith Geva in:

  12. Search for Amy E Roberts in:

  13. Search for Qing Ma in:

  14. Search for Jian Ding in:

  15. Search for Jinghai Chen in:

  16. Search for Da-Zhi Wang in:

  17. Search for Kai Li in:

  18. Search for Jiwu Wang in:

  19. Search for Ronald J A Wanders in:

  20. Search for Wim Kulik in:

  21. Search for Frédéric M Vaz in:

  22. Search for Michael A Laflamme in:

  23. Search for Charles E Murry in:

  24. Search for Kenneth R Chien in:

  25. Search for Richard I Kelley in:

  26. Search for George M Church in:

  27. Search for Kevin Kit Parker in:

  28. Search for William T Pu in:


G.W. designed and performed experiments and analyzed data. M.L.M. designed and performed experiments on MTFs and sarcomere organization and analyzed data. L.Y. and G.M.C. provided expert assistance and reagents for genome editing. F.S.P. designed the sarcomere organization analysis method. H.Y. developed the MTF analysis method. A.A. assisted with MTF substrate fabrication and experiments. D.J. provided advice on mitochondrial assays. D.Z. imaged iPSC-CMs to assess their mitochondrial organization and potential. L.Z. and K.R.C. provided expert assistance with modRNA, and J.C., J.D. and D.-Z.W. helped construct modRNAs. K.L. contributed to genome editing. R.J.A.W., W.K. and F.M.V. analyzed phospholipids. M.A.L. and C.E.M. provided expert assistance in iPSC differentiation to cardiomyocytes. A.H. developed TAZ shRNA viruses and provided technical assistance. J.G. and A.E.R. obtained patient samples. Q.M. assisted in teratoma analysis. J.W. contributed control iPSC lines. R.I.K. provided expert input, patient samples and 31P nuclear magnetic resonance data. K.K.P. and W.T.P. supervised the study. W.T.P. wrote the manuscript, and it was revised by K.K.P., G.W. and M.L.M.

Competing interests

J.W. is an employee of Allele Biotechnology & Pharmaceuticals.

Corresponding authors

Correspondence to Kevin Kit Parker or William T Pu.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Tables 1–4 and Supplementary Figures 1–14

  2. 2.

    Supplementary Movies

    Supplementary Movies 1–6

Excel files

  1. 1.

    Supplementary Data Set

    Supplementary Data Sets

About this article

Publication history





Further reading